Introduction
============

Breast cancer is a serious life-threatening condition affecting women worldwide.[@b1-bctt-9-045] It ranks second among various causes of cancer death in women.[@b2-bctt-9-045] In Jordan, 42.9% of cancers diagnosed in women are breast cancers.[@b3-bctt-9-045] Understanding the pathogenesis of breast cancer is important in the innovative therapies for breast cancer diagnosis and treatment. One of the most important risks of breast cancer is endogenous hormone level. The genes of estrogen receptor (ER) pathway may influence breast cancer risk by two possible mechanisms: 1) ER-mediated stimulation of breast cell proliferation with a concomitant enhanced rate of mutations and 2) metabolism of estradiol to genotoxic metabolites with a resulting increase in DNA mutations.[@b4-bctt-9-045]

Estrogen is a steroid hormone that is essential for the development of female secondary sexual characters.[@b4-bctt-9-045] Under normal conditions, it affects the growth, differentiation and function of breast,[@b5-bctt-9-045] uterus, vagina, ovary, testis, epididymis and prostate.[@b6-bctt-9-045] However, under abnormal conditions, exposure to estrogen predisposes females to a risk of developing breast cancer. Current hormonal therapies have benefited breast cancer patients. However, their success is often limited to patients whose tumors express ERα, but entirely ineffective in ER-negative breast cancers.[@b7-bctt-9-045]

ERs are of special interest as their expression is always affected in malignant cancer cells.[@b8-bctt-9-045] ERs are nuclear receptor proteins that have an estrogen-binding domain and a DNA-binding domain.[@b9-bctt-9-045] There are two types of ERs: 1) ERα that is localized on 6q25.1 and associated with breast cancer and 2) ERβ that is located on chromosome 14q22-24 and functions as a tumor suppressor.[@b10-bctt-9-045] Polymorphisms in the ER genes may determine the biosynthetic activity of circulating estrogen.

Nearly over half of all types of breast cancers overexpress ERα and \~70% of these respond to anti-estrogen.[@b11-bctt-9-045] Elevated levels of ERα in benign breast epithelium indicate an increased risk of breast cancer.[@b12-bctt-9-045] ERα status is essential in making decisions about endocrine therapy with anti-estrogen since ERα (+) status correlates with improved prognosis and better overall survival.[@b9-bctt-9-045]

ERα is regarded as one of the significant prognostic factors for breast, ovarian and lung cancers,[@b13-bctt-9-045] miscarriage and endometriosis. Single nucleotide polymorphisms were associated with increased risk of cancers.[@b14-bctt-9-045] The most characterized single nucleotide polymorphisms of ERα located in the first intron are the c454-397T\>C- and c454-351A\>G-site polymorphisms. These polymorphisms are 397 and 351 base pairs upstream of exon 2 and are detected by restriction enzymes *PvuII* or *XbaI*, respectively.[@b15-bctt-9-045] These polymorphisms were correlated with breast cancer incidence.[@b16-bctt-9-045] *PvuII* altered protein expression by interfering with ERα mRNA splicing, but the mechanism of action of *XbaI* is still unknown.

Genetic studies on cancer are scarce in Jordan and only few studies have screened gene polymorphism in breast cancer.[@b17-bctt-9-045]--[@b20-bctt-9-045] To our knowledge, no studies have determined the role of ERα *PvuII* and *XbaI* polymorphisms in breast cancer susceptibility among Jordanians. Therefore, the aim of this study was to determine the frequency of ERα *PvuII* and *XbaI* genotypes and the possible involvement of these polymorphisms in breast cancer susceptibility among Jordanian women with breast cancer.

Materials and methods
=====================

This study enrolled 156 women who were histologically and clinically diagnosed with breast cancer and 142 age-matched controls with no previous family history of any cancer from Al-Basheer Hospital (2013--2015). International review board approval was obtained from the Hashemite University international review board committee and signed consent forms were obtained from all patients. All clinical samples were staged according to Atoum et al.[@b21-bctt-9-045]

Genomic DNA was extracted from all blood samples using Wizard extraction kit (Promega, Madison, WI, USA) and was stored at −80°C. Polymerase chain reaction was carried out to amplify intron 1--exon 2 region of ERα gene in three steps with annealing at 60°C in a thermal cycler (Bio-Rad, Munich, Germany) in 25 μL reaction volume. Each reaction mixture contained 10 pmol of each primer, 3 mM of MgCl~2~, 100 nM of each deoxynucleotide triphosphate, 1 unit of Taq DNA polymerase and 100 ng of genomic DNA. Primer sequences are as follows: forward primer: 5′ AGG GTT ATG TGG CAA TGA CG 3′; reverse primer: 5′ CCT GCA CCA GAA TAT GTT ACC T 3′. The amplified fragment of 1374 base pairs was then digested with *PvuII* and *XbaI*. The presence of *PvuII* restriction site on both alleles (pp) was identified by two fragments (850, 450), while the presence of *XbaI* on both alleles (xx) was identified by two fragments (900, 400). Digested fragments were then electrophoresed on 1.5% agarose gel with ethidium bromide.

Statistical analysis
--------------------

Statistical analysis was carried out using SPSS software. The distribution of genotypes in cancer patients and controls was evaluated by the Chi-square test. Odds ratio (OR) and 95% confidence interval (CI) were used to estimate the relative risk. A *p*-value \<0.05 was considered statistically significant.

Results
=======

Genotypic distribution of ERα *PvuII* and *XbaI* is shown in [Table 1](#t1-bctt-9-045){ref-type="table"}. With reference to PP genotype, no significant associations were found between the variations of breast cancer risk and P alleles in homozygotes or heterozygotes. There was no statistical difference in the prevalence of P allele between cases (84.6%) and controls (86.6%). Nearly 15.4% of the patients and 13.4% of the controls were homozygous for P allele. About 55.8% of the patients and 57.7% of the controls were heterozygous for this allele. No significant association was found between breast cancer risk and P allele in heterozygotes (OR 1.19, 95% CI 0.61--2.33) or homozygotes (OR 1.15, 95% CI 0.55--2.40). A statistical difference was observed in the prevalence of X allele between cases (75%) and controls (93.7%). *XbaI* polymorphism in x allele was more prevalent among controls (35.9%) compared to patients with breast cancer (29.5%), (OR 0.208, 95% CI 0.09--0.47).

Combined analysis of *PvuII* and *XbaI* genotypes revealed a synergistic effect of Pp/Xx (OR 0.11, 95% CI 1.19--9.66, *p* = 0.03) and pp/xx (OR 0.11, 95% CI 0.02--0.58, *p* = 0.01) as carriers of these genotypes showed reduced risk of breast cancer ([Table 2](#t2-bctt-9-045){ref-type="table"}).

[Table 3](#t3-bctt-9-045){ref-type="table"} shows the histological subtypes of different *PvuII* and *XbaI* genotypes among women with breast cancer. No statistical difference was found within either *PvuII* or *XbaI* genotypes (*p* = 0.83, 0.81, respectively) among different breast cancer stages.

No statistical differences were found among *PvuII* or *XbaI* polymorphisms based on ER, progesterone receptor and expression of hormone receptor such as human epidermal growth factor receptor 2 (HER2) ([Table 4](#t4-bctt-9-045){ref-type="table"}).

Discussion
==========

This case--control study was conducted to analyze the association between *PvuII* and *XbaI* polymorphisms and breast cancer risk among Jordanian females. No association between the variation of breast cancer risk and pp genotype was found compared to PP genotype, but a significant association was found between reduced breast cancer risk and xx genotype compared to XX genotype. Also no association was found between the variation of breast cancer risk and *PvuII* or *XbaI* genotypes based on breast cancer stages, presence of ER, progesterone receptor and expression of hormone receptor HER2 among breast cancer females. The results of this study are in contrast with those of a Chinese study that analyzed *PvuII* and *XbaI* for breast cancer risk. A significant association was found between Pp and pp genotypes and increased breast cancer risk, whereas no significant association was found between Xx and xx genotypes and increased breast cancer risk.[@b22-bctt-9-045] The results of this study are also in contrast with the results of another Chinese study that was conducted among another Chinese group[@b23-bctt-9-045]; the results showed no effect of *PvuII* and *XbaI* polymorphisms on breast cancer risk. This study showed a significant association between reduced breast cancer risk and xx genotype, in contrast to the results of a study on Pakistani breast cancer patients,[@b24-bctt-9-045] and similar to the results of a study on Portuguese population where xx genotype was associated with decreased breast cancer risk.[@b16-bctt-9-045] This contradiction may be due to the large and different biological processes where alpha estrogens and their receptors are involved. The possible mechanisms by which *PvuII* and *XbaI* polymorphisms affect breast cancer are still not known. The position of *PvuII* and *XbaI* polymorphisms in the intron near the promoter may contain regulatory sequences like enhancers that affect the expression of alpha receptor gene. Intronic enhancers act as regulatory sequences that control transcriptional regulation.[@b25-bctt-9-045] Nowadays, ERα has been signaled as a possible marker for many diseases, including different cancers and immunological diseases.

Conclusion
==========

The results of this case--control study showed a significant reduction in breast cancer risk in women carrying xx genotype. So further studies are needed with larger sample size among different populations to clarify how ERα and *XbaI* may modify an individual's susceptibility to breast cancer risk.
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###### 

Frequency of estrogen receptor alpha polymorphism *PvuII* and *XbaI* among breast cancer patients and controls

  Genotype   Cases n=156, n (%)   Controls n=142, n (%)   OR      95% CI       *p*-value
  ---------- -------------------- ----------------------- ------- ------------ -----------
  PP         24 (15.4)            19 (13.4)               1       NA           NA
  Pp/pp      132 (84.6)           123 (86.6)              1.18    0.61--2.25   0.62
  Pp         87 (55.8)            82 (57.7)               1.19    0.61--2.33   0.61
  pp         45 (28.8)            41 (28.9)               1.15    0.55--2.40   0.71
  XX         39 (25)              9 (6.3)                 1       NA           NA
  Xx/xx      117 (75)             133 (93.7)              0.203   0.09--0.43   0.0001
  Xx         71 (45.5)            82 (57.7)               0.199   0.09--0.44   0.0001
  xx         46 (29.5)            51 (35.9)               0.208   0.09--0.47   0.0002

**Note:** Significant *p*-value \<0.05.

**Abbreviations:** CI, confidence interval; OR, odds ratio; NA, not available.

###### 

Breast cancer risk in relation to *PvuII* and *XbaI* combination genotypes

  Genotype   Cases   Control   OR      95% CI        *p*-value
  ---------- ------- --------- ------- ------------- -----------
  PP/XX      8       2         1       NA            NA
  PP/Xx      10      8         0.31    0.05--1.90    0.20
  PP/xx      6       14        0.107   0.01--0.66    0.16
  Pp/XX      23      4         0.70    1.19--29.66   0.70
  Pp/Xx      35      52        0.11    1.19--9.66    0.03
  Pp/xx      29      31        0.28    0.04--1.19    0.08
  pp/XX      8       3         0.67    0.08--5.12    0.69
  pp/Xx      26      2         3.25    0.39--26.91   0.27
  pp/xx      11      26        0.11    0.02--0.58    0.01

**Note:** Significant *p*-value \<0.05.

**Abbreviations:** CI, confidence interval; OR, odds ratio; NA, not available.

###### 

Breast cancer patient stages among *PvuII* and *XbaI* genotypes

  Cancer genotype   Stage I   Stage II   Stage III   Stage IV   Total   *p*-value
  ----------------- --------- ---------- ----------- ---------- ------- -----------
  PP                1         7          11          5          24      0.83
  Pp                1         22         35          29         87      
  pp                1         12         21          11         45      
  XX                0         11         19          9          39      0.81
  Xx                2         20         37          12         71      
  xx                0         14         23          9          46      

**Note:** Significant *p*-value \<0.05.

###### 

Estrogen receptor, progesterone receptor and hormone receptor HER2 among breast cancer cases

  Cancer genotype   ER positive   PR positive   HER2 positive   *p*-value
  ----------------- ------------- ------------- --------------- -----------
  PP                13            17            9               0.19
  Pp                48            51            11              
  pp                21            28            13              
  Total             82            96            33              
  XX                11            15            7               0.43
  Xx                53            50            12              
  xx                23            26            10              
  Total             87            91            29              

**Abbreviations:** ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.
